Compare Enveric Biosciences Inc (ENVB) vs Robinhood Markets, Inc. (HOOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Robinhood Markets, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Robinhood Markets, Inc. trades at $108.78 (market cap $96.21B). The key difference: Robinhood Markets, Inc. is far larger — about 14148.5× Enveric Biosciences Inc's market cap, and Robinhood Markets, Inc. is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Robinhood Markets, Inc. for 75 Days on average.
| ENVB | HOOD | |
|---|---|---|
Market Cap | $6.80M | $96.21B |
Volume | 64,867 | 22,572,153 |
Sector | Health | Financials |
52-Week High | $10.80 | $152.46 |
52-Week Low | $1.27 | $65.16 |
Typical Hold Time | 14 Days | 75 Days |
Enterprise Value | -$1.49M | $102.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Robinhood (HOOD) trades at $109.51, down 2.22% today, with strong technical support at $108. The stock shows robust fundamentals with 2025 revenue reaching $4.47B and net income of $1.88B, representing 42% margins. Recent news highlights expansion into 24/7 stock trading and new product launches, positioning the company for continued growth in the e-brokerage sector.
Wall Street maintains a bullish outlook with 77% buy ratings and a $137 consensus price target, representing 25% upside potential. Key risks include valuation concerns with a 48.5 P/E ratio and execution challenges in new product rollouts. The company's transformation into a broader financial services platform provides long-term growth opportunities despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →
